about
Immunoglobulin replacement therapy reduces chronic rhinosinusitis in patients with antibody deficiency.Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma.Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts.Recurrent infections, pericarditis and renal disease in a patient with total C2 deficiency and decreased NK cell function consistent with acute rheumatic fever and systemic lupus erythematosus.Immune dysfunction in refractory sinusitis in a tertiary care setting.Assessing siRNA pharmacodynamics in a luciferase-expressing mouse.Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis.Glycosylation contributes to variability in expression of murine cytomegalovirus m157 and enhances stability of interaction with the NK-cell receptor Ly49H.The Glycophosphatidylinositol Anchor of the MCMV Evasin, m157, Facilitates Optimal Cell Surface Expression and Ly49 Receptor Recognition.Novel role for endogenous hepatocyte growth factor in the pathogenesis of intracranial aneurysms.Natural killer cells: emerging concepts in immunity to infection and implications for assessment of immunodeficiency.Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemiaAntibody deficiency in patients with frequent exacerbations of Chronic Obstructive Pulmonary Disease (COPD).Evaluation of the adult with suspected immunodeficiency.A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma.Biologic response modifiers: Indications, implications, and insights.Significance of Hyperferritinemia in Hospitalized Adults.Gastrointestinal Manifestations in X-linked Agammaglobulinemia.CpG DNA induces cyclooxygenase-2 expression and prostaglandin production.Neurohormonal modulation of the innate immune system is proinflammatory in the prehypertensive spontaneously hypertensive rat, a genetic model of essential hypertension.Nicotine Mediates CD161a+ Renal Macrophage Infiltration and Premature Hypertension in the Spontaneously Hypertensive Rat.Idiopathic systemic capillary leak syndrome: novel therapy for acute attacks.A patient with simultaneous absence of "classical" natural killer cells (CD3-, CD16+, and NKH1+) and expansion of CD3+, CD4-, CD8-, NKH1+ subset.Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes.Chronic ethanol ingestion by mice increases expression of CD80 and CD86 by activated macrophages.Murine natural killer cells express the Ly24 (Pgp-1) marker on their surface.Eosinophilic fasciitis masquerading as angioedema.A novel therapy for lymphedema.A Personalized Diagnostic and Treatment Approach for Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Adults.Immune response modifiers in the treatment of asthma: A PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology.Practice parameter for the diagnosis and management of primary immunodeficiency.The effects of intravenous endotoxin on various host-effector molecules.CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma☆☆☆★Substance P does not alter interleukin-1 expression by splenic or granuloma macrophages in murine schistosomiasisLymphokine-activated killer (LAK) cells. VI. NK1.1+, CD3+ LAK effectors are derived from CD4-, CD8-, NK1.1- precursorsAlteration of human accessory cell function by heat treatment: role of IL-1 and class II MHC antigensInterleukin 2 induces interferon alpha/beta production in mouse bone marrow cellsAnti-pneumococcal antibody response in normal subjects: a meta-analysisFine T-cell subsets in alcoholics as determined by the expression of L-selectin, leukocyte common antigen, and beta-integrinModulation of T-cell adhesion markers, and the CD45R and CD57 antigens in human alcoholics
P50
Q30276076-CEC41344-5544-4381-918D-4523D5307E8CQ33372646-70943A52-D8E7-40AA-B82E-348A801F4650Q33563416-4422E9AA-236C-4E1A-8C5A-8FC3857B8A94Q33566301-39C57A7A-AAA3-4543-83A0-4E8A557520A7Q34157896-2B638EBB-F4DE-45BB-8271-2886393D0742Q34457509-C0CECAA7-800D-41B8-95D1-19638B6BB10CQ34480913-6993106B-446D-41BA-A706-0EE63024A73DQ34759678-A755D9D2-C51E-42C0-B43C-D5F34DF316EBQ34806981-0B42DF70-9EBD-4264-96EA-0A648A5FC938Q35079472-81CE3760-24E2-4A00-B7F8-7794CC37C54AQ35590296-8C822A9C-AAB4-4D5B-8A34-EA7566244054Q36222910-C5F4684A-315C-457A-8E16-B1C73368A8D7Q36284254-F01D61B5-30F4-4960-8436-26B966368B2DQ36926353-F7C0EFF9-F281-41D8-BB1E-62C597EC1A5DQ38259725-E56FF8DA-5147-4E34-9479-44E0F58ADA2AQ39163945-5DE945F5-7DED-4EEF-A9AB-B600100EA00FQ40060993-B0F3C4C9-E196-4AE4-8FCE-FBC4FF2B2016Q40318352-1115DD44-7001-4528-A843-3A53C5F10338Q40790193-96F2C14F-AF41-4CD4-B95C-48139F07A7F3Q42151474-309CCCE2-9B33-463C-8D1F-27B38A7381A6Q42723817-AC07493A-767A-46FE-88B0-21AAB0B7EAF9Q43286855-01CC9001-D0A7-4940-BB31-E284062DFCBFQ43843762-4BEBD672-2841-402A-8B81-6D8EC6FB62E8Q44090015-1E636533-5B7B-45A3-BBB5-17EBE5336488Q44910988-D07ABB0E-28A1-4B75-B3E0-B376BB094B0FQ45189905-D98BEBD0-F2FA-4FC5-82B7-921D12581408Q46057088-DC176957-DEFE-47E6-9C3E-63B4296ABFB7Q46145610-EB3A6F99-2949-48BF-B08E-62659139B4E4Q47651267-C78A551E-632F-4ADA-9050-10693DB2B0F0Q53161786-DE7238C3-20C7-410B-B656-ABCA9CA099DDQ53350455-3BA24067-F028-4A35-9882-AF7B52F8DE89Q54720079-A70575B9-9B86-49B6-A178-F8A274D3931AQ60147719-18A0413B-2529-43A8-B3AE-69858CC003BEQ67697834-4C8A9047-314F-467C-947A-61EF1FCB09A2Q67898885-CBA7282C-6A3E-4979-ADD7-3CDC49086FD4Q68800289-468A7FE1-B5FB-4C4B-A57A-5D9F5047E46DQ70320306-8353FA05-4746-4F73-8161-0E3720CD7CA6Q71423334-69E2F09E-1FD9-4450-879B-DE05E9E28852Q71625499-1563BAFA-3A40-47DE-B082-D47571489B96Q71776855-2F19EB67-7482-40D8-B228-EA94DCF2BFB4
P50
description
researcher ORCID ID = 0000-0001-5569-1230
@en
wetenschapper
@nl
name
Zuhair K Ballas
@ast
Zuhair K Ballas
@en
Zuhair K Ballas
@es
Zuhair K Ballas
@nl
type
label
Zuhair K Ballas
@ast
Zuhair K Ballas
@en
Zuhair K Ballas
@es
Zuhair K Ballas
@nl
prefLabel
Zuhair K Ballas
@ast
Zuhair K Ballas
@en
Zuhair K Ballas
@es
Zuhair K Ballas
@nl
P106
P1153
7005978614
P31
P496
0000-0001-5569-1230